One high affinity CD1c specific TCR variant (S2ca5b6) was reformatted as bispecific molecules by fusing it to an anti-CD3 scFv to produce immune mobilising monoclonal TCRs against cancer (ImmTACs, Supplementary Figure S4C) (44). This evidence concerns the gene CD1C and cancer.